Division of Hematology/Oncology, University of Florida College of Medicine, Gainesville, Florida.
Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin; CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Transplant Cell Ther. 2022 Sep;28(9):603.e1-603.e7. doi: 10.1016/j.jtct.2022.05.042. Epub 2022 Jun 7.
There is a lack of evidence about how health-related quality of life (HRQoL), including psychosocial factors, might affect donation-related experiences and clinical markers in the context of hematopoietic stem cell donation. The broader literature suggests that psychological factors, including anxiety and depression, are associated with higher levels of inflammatory burden leading to poorer postprocedural outcomes including longer hospital stays and increased pain perception. In this study, we aimed to evaluate whether predonation HRQoL markers predict toxicity profile and stem cell yield after peripheral blood stem cell (PBSC) donation in healthy donors. The study population comprised adult granulocyte colony-stimulating factor mobilized PBSC-related donors (RD) (n = 157) and unrelated donors (URD) (n = 179) enrolled in the related donor safety study (RDSafe) and Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0201 clinical trials. Pre-donation HRQoL was assessed using the Short-Form-12 (SF-12) in RDSafe and SF-8 questionnaire in BMT CTN 0201 (higher score is better). The aims of this study were to (a) determine the impact of pre-donation HRQoL on peri-collection pain and acute toxicities experienced and (b) to investigate the pre-procedural HRQoL indicators on stem cells yield. URDs were younger than RDs (median age 35 versus 63). A higher proportion of RDs were female (50% versus 40%) and obese (41% versus 35%). A higher proportion of RD PBSC donations required 2 days or more of apheresis (44% versus 21%). More RD collections were lower volume procedures (<18L, 16% versus 28%), and required a central line (28% versus 11%). RDs were more likely to report pre-donation grade 1-2 pain (27% versus 8%) and other toxicities (16% versus 6%). Among RDs, a lower pre-donation physical component summary (PCS) score was associated with significantly more grade 2-4 pain at 1 month (P = .004) and at 1-year after donation (P = .0099) in univariable analyses. In multivariable analysis, pre-donation PCS remained significantly associated with grade 2-4 pain 1 month after donation (P = .0098). More specifically, RDs with predonation PCS scores in the highest quartile were less likely to report pain compared with donors with PCS scores in the lowest quartile (odds ratio 0.1; 95% confidence interval 0.01-0.83; P = .005). There was also a trend toward higher grade 2-4 pain at 1-year post-donation among RDs with lower predonation PCS score (P = .018). Among URDs, neither PCS nor mental component summary (MCS) scores were associated with pain or toxicities at any time point after donation based on the univariable analysis. Because of low rates of postdonation grade 2-4 pain and toxicities, multivariable analysis was not performed in the URD setting. Moreover, there was no correlation between preapheresis HRQoL score (PCS or MCS) and PBSC collection yield in either the RD or URD setting. Our study demonstrates that pre-donation HRQoL scores are significantly associated with the toxicity profile after PBSC donation in the RD setting, with adult RDs with lower predonation physical HRQoL experiencing higher levels of pain at 1 month and persisting up to 12 months after a PBSC collection procedure. There were no such associations found in URD. Our findings can help clinicians identify donors at higher risk of pain with donation, and lead to personalized information and interventions for specific donors. Lack of correlation between predonation HRQoL and stem cell yield may be due to a small sample size and warrants further evaluation.
目前关于健康相关生活质量(HRQoL),包括心理社会因素,如何影响造血干细胞捐献背景下的捐献相关体验和临床标志物,相关证据有限。更广泛的文献表明,心理因素,包括焦虑和抑郁,与更高水平的炎症负担有关,导致术后结果更差,包括住院时间延长和疼痛感知增加。在这项研究中,我们旨在评估供体在接受外周血造血干细胞(PBSC)捐献前的 HRQoL 标志物是否可以预测毒性特征和干细胞产量。研究人群包括接受粒细胞集落刺激因子动员的 PBSC 相关供体(RD)(n=157)和无关供体(URD)(n=179),他们参加了相关供体安全研究(RDSafe)和血液和骨髓移植临床试验网络(BMT CTN)0201 临床试验。在 RDSafe 中使用简短形式-12(SF-12)评估供体在接受采集前的 HRQoL,在 BMT CTN 0201 中使用 SF-8 问卷(得分越高越好)。本研究的目的是:(a)确定供体在采集前的 HRQoL 对围采集期疼痛和急性毒性的影响;(b)调查术前 HRQoL 指标对干细胞产量的影响。URD 比 RD 更年轻(中位数年龄 35 岁对 63 岁)。RD 中女性(50%对 40%)和肥胖(41%对 35%)的比例更高。RD 的 PBSC 捐献需要 2 天或更长时间的单采(44%对 21%)。更多 RD 采集为低容量程序(<18L,16%对 28%),需要中央静脉置管(28%对 11%)。RD 更有可能报告在采集前 1 级-2 级疼痛(27%对 8%)和其他毒性(16%对 6%)。在 RD 中,在单变量分析中,与捐赠前物理成分综合评分(PCS)较低的 RD 相比,在 1 个月(P=0.004)和 1 年后(P=0.0099),1 级-2 级疼痛的发生率显著更高。在多变量分析中,PCS 仍与捐赠后 1 个月的 2 级-4 级疼痛显著相关(P=0.0098)。更具体地说,与 PCS 评分最低四分位数的供体相比,PCS 评分最高四分位数的 RD 报告疼痛的可能性更小(比值比 0.1;95%置信区间 0.01-0.83;P=0.005)。RD 捐赠前 PCS 评分较低与 1 年后更高的 2 级-4 级疼痛也有趋势相关(P=0.018)。在 URD 中,基于单变量分析,PCS 或心理成分综合评分(MCS)均与捐赠后任何时间点的疼痛或毒性无关。由于捐赠后 2 级-4 级疼痛和毒性的发生率较低,因此未在 URD 中进行多变量分析。此外,在 RD 或 URD 中,在采集前 HRQoL 评分(PCS 或 MCS)与 PBSC 采集产量之间均无相关性。我们的研究表明,在 RD 环境中,供体在接受 PBSC 捐献前的 HRQoL 评分与 PBSC 捐献后的毒性特征显著相关,RD 中的成年供体在采集前的生理 HRQoL 评分较低,在 1 个月时经历更高水平的疼痛,并持续至 PBSC 采集后 12 个月。URD 中未发现此类关联。我们的研究结果可以帮助临床医生识别有疼痛风险的供体,并为特定供体提供个性化的信息和干预措施。供体在采集前的 HRQoL 与干细胞产量之间缺乏相关性可能是由于样本量较小,需要进一步评估。